ProCE Banner Activity

PARP Inhibitors in Recurrent Ovarian Cancer

Slideset Download

In this downloadable slideset, CCO’s expert faculty reviews PARP inhibitors in the treatment of patients with recurrent ovarian cancer.

This slideset is intended for clinicians practicing medicine outside of the United States.

Released: December 22, 2020

Expiration: December 21, 2021

No longer available for credit.

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts